USE OF STEM CELLS IN REGENERATIVE CARDIOVASCULAR MEDICINE (Review Article)
DOI:
https://doi.org/10.52340/jecm.2022.02.17Abstract
Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide, with its lifetime risk exceeding over 60%. Though various medications and procedures have managed to play a role in reducing mortality, none have shown to be permanent. The idea of stem cells is to generate an original solution that provides normal physiological responses. When applied to cardiology, it holds tremendous promise for rapid myocardial regeneration. The selection of the most appropriate type of cell is essential for its efficient application. If done successfully, it will negate temporary solutions such as a stent, defibrillators, and medications. This article discusses all the studies that applied stem cells in cardiac pathologies and reveals the benefits as well as outcomes. It helps us understand the limitations one may come across while experimenting in this field and introduces issues that will need further research.
Downloads
References
Abou-Saleh H, ZoueinAF, EI-Yazbi A, et al. The march of pluripotent stem cells in cardiovascular regenerative medicine. Stem Cell Research & Therapy 2018;9(1):201.
Mahla RS. Stem Cells Applications in Regenerative Medicine and Disease Therapeutics. International journal of cell biology 2016:6940283.
Lemcke H, Voronina N, Steinhoff G, David R. Recent Progress in Stem Cell Modification for Cardiac Regeneration. Stem Cells International 2018:1909346.
Pagani FD, DerSimonian H, Zawadzka A, et al. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans: Histological analysis of cell survival and differentiation. Journal of the American College of Cardiology 2003;41(5):879-88.
Stoltz J-F, De Isla N, Li YP, et al. Stem Cells and Regenerative Medicine: Myth or Reality of the 21th Century. Stem Cells International 2015:734731.
Mummery CL, Zhang J, Elizabeth S Ng, et al. Differentiation of Human Embryonic Stem Cells and Induced Pluripotent Stem Cells to Cardiomyocytes: a methods overview. Circulation Research. American Heart Association 2012;111(3):344-58.
Fernandes S, Chong JH, Paige SL, et al. Comparison of Human Embryonic Stem Cell-Derived Cardiomyocytes, Cardiovascular Progenitors, and Bone Marrow Mononuclear Cells for Cardiac Repair. Stem Cell Reports 2015;5(5):753-62.
Oh Y, Wei H, Ma D, Sun X, Liew R, Clinical applications of patient-specific induced pluripotent stem cells in cardiovascular medicine. Heart (British Cardiac Society) 2012;98(6):443-49.
Frese L, Dijkman PE, Hoerstrup SP. Adipose Tissue-Derived Stem Cells in Regenerative Medicine. Transfusion Medicine and Hemotherapy 2016;43(4):268-74.
Müller P, Lemcke H, David R. Stem Cell Therapy in Heart Diseases – Cell Types, Mechanisms and Improvement Strategies. Cellular Physiology and Biochemistry 2018;48(6):2607-55.
Karantalis V, Hare JM. Use of mesenchymal stem cells for therapy of cardiac disease. Circulation research 2015;116(8):1413-30.
Durrani S, Konoplyannikov M, Ashraf M, Haider KH. Skeletal myoblasts for cardiac repair. Regenerative medicine 2010;5(6):919-32.
Strauer BE, Brehm M, Zeus T, et al. Regeneration of Human Infarcted Heart Muscle by Intracoronary Autologous Bone Marrow Cell Transplantation in Chronic Coronary Artery Disease: The IACT Study. Journal of the American College of Cardiology 2005;46(9):1651-58.
Nir SG, David R, Zaruba M, FranzWM, Wolfgang-M, Itskovitz-Eldor J, Human embryonic stem cells for cardiovascular repair. Cardiovascular Research 2003;58(2):313-23.
Bruun K, Schermer E, Sivendra A, et al. Therapeutic applications of adipose-derived stem cells in cardiovascular disease. American journal of stem cells 2018;7(4):94-103.
Guo R, Morimatsu M, Feng T, et al. Stem cell-derived cell sheet transplantation for heart tissue repair in myocardial infarction. Stem Cell Research & Therapy 2020;11(1):19.
Li P, Li S-H, Wu J, et al. Interleukin-6 downregulation with mesenchymal stem cell differentiation results in loss of immunoprivilege. Journal of cellular and molecular medicine 2013;1136-4517(9):1136-45.
Gladstone DE, Bettinotti MP, HLA donor-specific antibodies in allogeneic hematopoietic stem cell transplantation: challenges and opportunities. American Society of Hematology 2017; 1:645-650.
Mattapally S, PawlikKM, Fast VG, et al. Human Leukocyte Antigen Class I and II Knockout Human Induced Pluripotent Stem Cell-Derived Cells: Universal Donor for Cell Therapy. Journal of the American Heart Association 2018;7(23)e010239.
Bagno L, Hatzistergos KE, Balkan W, Hare JM. Mesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges. Molecular therapy: the journal of the American Society of Gene Therapy 2018;26(7):1610-23.
Omer A, Barrera MC, Moran JL, et al. G3BP1 controls the senescence-associated secretome and its impact on cancer progression. Nature Communications 2020;11(1):4979.
Denu RA. SIRT3 Enhances Mesenchymal Stem Cell Longevity and Differentiation. Oxidative medicine and cellular longevity 2017:5841716.
Menasche P, Hagège AA, Vilquin J-T, et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. Journal of the American College of Cardiology 2003;41(7):1078-83.
Seidel M, Borczyńska A, Rozwadowska N, Kurpisz M. Cell-Based Therapy for Heart Failure: Skeletal Myoblasts 2009;18(7),695-07.
Downloads
Published
How to Cite
Issue
Section
